[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ardelyx Inc (ARDX)

Ardelyx Inc (ARDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,459,220
  • Shares Outstanding, K 245,247
  • Annual Sales, $ 407,320 K
  • Annual Income, $ -61,600 K
  • EBIT $ -41 M
  • EBITDA $ -38 M
  • 60-Month Beta 0.66
  • Price/Sales 3.59
  • Price/Cash Flow N/A
  • Price/Book 8.67

Options Overview Details

View History
  • Implied Volatility 69.10% (-12.45%)
  • Historical Volatility 42.27%
  • IV Percentile 32%
  • IV Rank 22.08%
  • IV High 151.31% on 02/06/26
  • IV Low 45.81% on 08/21/25
  • Expected Move (DTE 18) 0.74 (12.35%)
  • Put/Call Vol Ratio 3.95
  • Today's Volume 727
  • Volume Avg (30-Day) 910
  • Put/Call OI Ratio 0.37
  • Today's Open Interest 46,075
  • Open Int (30-Day) 49,316
  • Expected Range 5.25 to 6.73

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.12
  • Number of Estimates 6
  • High Estimate $-0.09
  • Low Estimate $-0.15
  • Prior Year $-0.17
  • Growth Rate Est. (year over year) +29.41%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.35 +12.06%
on 03/30/26
6.54 -8.33%
on 04/17/26
+0.51 (+9.40%)
since 03/27/26
3-Month
5.11 +17.43%
on 03/24/26
8.06 -25.62%
on 01/28/26
-1.89 (-24.02%)
since 01/27/26
52-Week
3.21 +86.76%
on 05/15/25
8.40 -28.63%
on 01/23/26
+0.73 (+13.97%)
since 04/25/25

Most Recent Stories

More News
Ardelyx Announces Abstract Accepted for Poster Presentation at the NKF’s Spring Clinical Meetings

WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines...

ARDX : 5.99 (+0.67%)
Ardelyx Announces Abstract Exploring IBS-C Treatment Patterns Accepted for Poster Presentation at Digestive Disease Week 2026

WALTHAM, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines...

ARDX : 5.99 (+0.67%)
Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer

WALTHAM, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant...

ARDX : 5.99 (+0.67%)
BMY : 58.15 (-0.95%)
Ardelyx to Report First Quarter 2026 Financial Results on April 30, 2026

WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX) (“Ardelyx” or the “Company”), a commercial-stage biopharmaceutical company focused on the development and commercialization...

ARDX : 5.99 (+0.67%)
Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx

WALTHAM, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant...

ARDX : 5.99 (+0.67%)
Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award

WALTHAM, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines...

ARDX : 5.99 (+0.67%)
Ardelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-C

WALTHAM, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant...

ARDX : 5.99 (+0.67%)
Ardelyx to Participate in Upcoming Investor Conferences

WALTHAM, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant...

ARDX : 5.99 (+0.67%)
Ardelyx and the LPGA Announce Multi-Year Partnership to Break Stigma Around Digestive Health Issues Impacting Millions

DAYTONA BEACH, Fla. and WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- The Ladies Professional Golf Association (LPGA) and Ardelyx (Nasdaq: ARDX), a biopharmaceutical company with a vision of creating...

ARDX : 5.99 (+0.67%)
Ardelyx: Q4 Earnings Snapshot

Ardelyx: Q4 Earnings Snapshot

ARDX : 5.99 (+0.67%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Bearish.

See More Share

Business Summary

Ardelyx, Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and commercializes small molecule therapeutics that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases. The Company's lead product candidate is Tenapanor which is in three ongoing Phase...

See More

Key Turning Points

3rd Resistance Point 6.22
2nd Resistance Point 6.13
1st Resistance Point 6.04
Last Price 5.99
1st Support Level 5.86
2nd Support Level 5.77
3rd Support Level 5.68

See More

52-Week High 8.40
Fibonacci 61.8% 6.42
Last Price 5.99
Fibonacci 50% 5.80
Fibonacci 38.2% 5.19
52-Week Low 3.21

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.